Astria Therapeutics (ATXS) News Today → Biden to Drop BOMBSHELL June 13th? (From Paradigm Press) (Ad) Free ATXS Stock Alerts $9.66 -0.05 (-0.51%) (As of 11:15 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13 at 2:55 AM | americanbankingnews.comAstria Therapeutics, Inc. (NASDAQ:ATXS) Forecasted to Post Q2 2024 Earnings of ($0.40) Per ShareMay 12 at 6:38 AM | americanbankingnews.comAstria Therapeutics (NASDAQ:ATXS) Shares Down 6.4% May 12 at 5:47 AM | americanbankingnews.comAstria Therapeutics (NASDAQ:ATXS) Rating Reiterated by HC WainwrightMay 12 at 5:47 AM | americanbankingnews.comAstria Therapeutics (NASDAQ:ATXS) Rating Reiterated by WedbushMay 11 at 10:11 AM | finance.yahoo.comWe're Not Very Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn RateMay 10, 2024 | marketbeat.comAstria Therapeutics' (ATXS) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $16.00 price objective on shares of Astria Therapeutics in a report on Friday.May 9, 2024 | markets.businessinsider.comATXS Stock Earnings: Astria Therapeutics Misses EPS for Q1 2024May 9, 2024 | businesswire.comAstria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate UpdateMay 9, 2024 | marketbeat.comVivo Capital LLC Buys 801,528 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS)Vivo Capital LLC boosted its stake in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 47.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,482,727 shares of the biotechnology company'sMay 8, 2024 | businesswire.comAstria Therapeutics to Present at Upcoming Society for Investigative Dermatology Annual MeetingMay 2, 2024 | businesswire.comAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 27, 2024 | marketbeat.comAstria Therapeutics, Inc. (NASDAQ:ATXS) is Vivo Capital LLC's 10th Largest PositionVivo Capital LLC reduced its position in Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 6.2% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,329,027 shares of the biotechnology company's stock after selling 153,70April 23, 2024 | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) Trading Down 2.9% on Analyst DowngradeAstria Therapeutics (NASDAQ:ATXS) Trading Down 2.9% After Analyst DowngradeApril 23, 2024 | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) Price Target Cut to $16.00 by Analysts at HC WainwrightHC Wainwright reduced their price objective on Astria Therapeutics from $18.00 to $16.00 and set a "buy" rating on the stock in a research report on Tuesday.April 17, 2024 | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) Stock Price Down 2.4%Astria Therapeutics (NASDAQ:ATXS) Shares Down 2.4%April 16, 2024 | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) Shares Up 2.9%Astria Therapeutics (NASDAQ:ATXS) Trading Up 2.9%April 9, 2024 | businesswire.comAstria Therapeutics Appoints Sunil Agarwal to Its Board of DirectorsApril 3, 2024 | finance.yahoo.comChief Medical Officer Christopher Morabito Sells 10,000 Shares of Astria Therapeutics Inc (ATXS)April 3, 2024 | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) Shares Down 3.4% Astria Therapeutics (NASDAQ:ATXS) Trading Down 3.4%March 31, 2024 | marketbeat.comAstria Therapeutics, Inc. (NASDAQ:ATXS) Short Interest UpdateAstria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) saw a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 2,010,000 shares, an increase of 18.2% from the February 29th total of 1,700,000 shares. Based on an average daily volume of 1,040,000 shares, the days-to-cover ratio is presently 1.9 days. Currently, 4.5% of the company's shares are sold short.March 27, 2024 | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) Sees Unusually-High Trading VolumeAstria Therapeutics (NASDAQ:ATXS) Sees Strong Trading VolumeMarch 26, 2024 | markets.businessinsider.comBuy Recommendation for Astria Therapeutics Backed by Promising ALPHA-STAR Trial ResultsMarch 26, 2024 | marketbeat.comWedbush Reiterates "Outperform" Rating for Astria Therapeutics (NASDAQ:ATXS)Wedbush reissued an "outperform" rating and set a $17.00 target price on shares of Astria Therapeutics in a research report on Tuesday.March 26, 2024 | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) Price Target Increased to $27.00 by Analysts at Jefferies Financial GroupJefferies Financial Group upped their target price on shares of Astria Therapeutics from $22.00 to $27.00 and gave the stock a "buy" rating in a research note on Monday.March 25, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY) and Astria Therapeutics (ATXS)March 25, 2024 | markets.businessinsider.comBuy Rating Affirmed for Astria Therapeutics on Promising STAR-0215 Data and Market PotentialMarch 25, 2024 | marketbeat.comAstria Therapeutics' (ATXS) Buy Rating Reaffirmed at HC WainwrightHC Wainwright restated a "buy" rating and issued a $18.00 target price on shares of Astria Therapeutics in a report on Monday.March 25, 2024 | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) Reaches New 12-Month High at $16.90Astria Therapeutics (NASDAQ:ATXS) Hits New 1-Year High at $16.90March 25, 2024 | markets.businessinsider.comAstria Therapeutics Reports Positive Initial Results From ALPHA-STAR Trial - Quick FactsMarch 25, 2024 | finance.yahoo.comAstria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAEMarch 23, 2024 | finance.yahoo.comAstria Therapeutics, Inc. (NASDAQ:ATXS) is favoured by institutional owners who hold 53% of the companyMarch 20, 2024 | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) Stock Price Down 6.9%Astria Therapeutics (NASDAQ:ATXS) Shares Down 6.9%March 19, 2024 | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) Trading Up 3.8%Astria Therapeutics (NASDAQ:ATXS) Shares Up 3.8%March 16, 2024 | marketbeat.comAstria Therapeutics, Inc. (NASDAQ:ATXS) Sees Significant Decline in Short InterestAstria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) was the recipient of a large decline in short interest during the month of February. As of February 29th, there was short interest totalling 1,700,000 shares, a decline of 13.3% from the February 14th total of 1,960,000 shares. Approximately 3.8% of the company's stock are sold short. Based on an average daily trading volume, of 790,400 shares, the short-interest ratio is presently 2.2 days.March 15, 2024 | finance.yahoo.comATXS Apr 2024 2.500 putMarch 15, 2024 | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) Hits New 52-Week High at $15.87Astria Therapeutics (NASDAQ:ATXS) Sets New 52-Week High at $15.87March 6, 2024 | marketbeat.comWedbush Comments on Astria Therapeutics, Inc.'s FY2028 Earnings (NASDAQ:ATXS)Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) - Wedbush issued their FY2028 earnings estimates for shares of Astria Therapeutics in a report issued on Monday, March 4th. Wedbush analyst L. Chico expects that the biotechnology company will post earnings per share of ($1.06) for the year. WMarch 5, 2024 | businesswire.comAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 5, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Avadel Pharmaceuticals (AVDL) and Astria Therapeutics (ATXS)March 5, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Arcellx Inc (ACLX), Astria Therapeutics (ATXS)March 5, 2024 | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) Shares Gap Down Following Weak EarningsAstria Therapeutics (NASDAQ:ATXS) Shares Gap Down After Earnings MissMarch 5, 2024 | marketbeat.comAstria Therapeutics' (ATXS) Outperform Rating Reaffirmed at WedbushWedbush reissued an "outperform" rating and set a $17.00 price target on shares of Astria Therapeutics in a report on Tuesday.March 5, 2024 | marketbeat.comAstria Therapeutics (NASDAQ:ATXS) Posts Quarterly Earnings Results, Misses Expectations By $0.08 EPSAstria Therapeutics (NASDAQ:ATXS - Get Free Report) released its quarterly earnings results on Monday. The biotechnology company reported ($0.86) earnings per share for the quarter, missing analysts' consensus estimates of ($0.78) by ($0.08).March 5, 2024 | marketbeat.comFmr LLC Sells 397,241 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS)Fmr LLC lessened its holdings in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 13.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,565,052 shares of the biotechnology company'sMarch 4, 2024 | businesswire.comAstria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate UpdateFebruary 27, 2024 | finance.yahoo.comATXS Oct 2024 22.500 callFebruary 20, 2024 | finance.yahoo.comAstria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma & Immunology Annual MeetingFebruary 20, 2024 | businesswire.comAstria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma & Immunology Annual MeetingFebruary 17, 2024 | finance.yahoo.comATXS Mar 2024 22.500 callFebruary 17, 2024 | finance.yahoo.comATXS Mar 2024 12.500 call Get Astria Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATXS and its competitors with MarketBeat's FREE daily newsletter. Email Address America’s worst nightmare? (Ad)What This Group Has Planned for the 2024 Election Will Shock You Controversial new exposé reveals what’s really going on in America, what it means for your money, and what you must do to protect your assets before it’s too late. Click here to watch this bombshell exposé now. ATXS Media Mentions By Week ATXS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATXS News Sentiment▼0.360.57▲Average Medical News Sentiment ATXS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATXS Articles This Week▼182▲ATXS Articles Average Week Get Astria Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATXS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Applied Therapeutics News Today Avid Bioservices News Today Arbutus Biopharma News Today COMPASS Pathways News Today Aerovate Therapeutics News Today Larimar Therapeutics News Today ArriVent BioPharma News Today Verve Therapeutics News Today Altimmune News Today KalVista Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ATXS) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperInvest Now: Starpax's Cancer Breakthrough Achieving What Others Haven't for a CenturyStarpaxHUGE BUY ALERT: Move Fast, Musk...Stansberry ResearchDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astria Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
